Oncolys BioPharma, Inc. (JP:4588)
:4588
Want to see JP:4588 full AI Analyst Report?
Top Page
Oncolys BioPharma, Inc.
(4588)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥2,430.00
▲(154.98% Upside)
Action:Reiterated
Date:05/23/26
The score is primarily constrained by weak financial performance—multi-year revenue collapse, ongoing large operating losses, and significant cash burn. Technicals provide partial support from a price-above-moving-averages structure, but negative MACD and low RSI signal soft momentum. Valuation offers limited support given ongoing losses (negative P/E) and no dividend yield provided.
Positive Factors
Balance-sheet strength / low leverage
The company's expanded equity and assets with modest debt (debt/equity ~0.12) provide a durable buffer against cash burn. This balance-sheet capacity improves access to financing, supports ongoing R&D spend and partnering negotiations, and reduces immediate liquidity pressure over months.
Negative Factors
Severe revenue collapse
A multi-year collapse in revenue signals lost or failed programs, waning partner income, or discontinued streams. Such a structural decline undermines the firm's ability to cover fixed R&D and G&A, makes recovery harder without new partners or approvals, and damages long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength / low leverage
The company's expanded equity and assets with modest debt (debt/equity ~0.12) provide a durable buffer against cash burn. This balance-sheet capacity improves access to financing, supports ongoing R&D spend and partnering negotiations, and reduces immediate liquidity pressure over months.
Read all positive factors
Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥74.05B
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue Growth0.80%
EPS Growth32.87%
CountryJP
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-93.11
Shares Outstanding29,306,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncolys BioPharma, Inc. Business Overview & Revenue Model
Company Description
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the U...
How the Company Makes Money
The company primarily makes money through drug development-related income rather than large-scale product sales. Key revenue streams typically include (1) collaboration and partnering revenue, such as upfront payments, research funding, developmen...
Oncolys BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.55M | 28.55M | 31.38M | 63.04M | 976.18M | 642.49M |
| Gross Profit | 27.68M | 28.30M | 31.38M | 30.61M | 338.49M | 198.80M |
| EBITDA | -2.18B | -2.05B | -1.68B | -1.93B | -1.14B | -1.60B |
| Net Income | -2.24B | -2.06B | -1.68B | -1.94B | -1.15B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 1.93B | 4.56B | 3.20B | 2.04B | 2.65B | 4.29B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 3.72B | 2.41B | 1.53B | 1.71B | 3.45B |
| Total Debt | 366.79M | 320.02M | 324.64M | 315.17M | 393.66M | 503.47M |
| Total Liabilities | 493.35M | 555.91M | 446.65M | 566.50M | 491.69M | 697.88M |
| Stockholders Equity | 1.44B | 4.00B | 2.75B | 1.47B | 2.16B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Operating Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Investing Cash Flow | 0.00 | -7.58M | -4.71M | -5.39M | 20.12M | -942.00K |
| Financing Cash Flow | 0.00 | 3.22B | 2.88B | 1.14B | -113.83M | 3.09B |
Oncolys BioPharma, Inc. Technical Analysis
Negative
953.00
Price Trends
2685.68
Negative
2491.43
Positive
1680.17
Positive
Market Momentum
-53.56
Positive
47.18
Neutral
47.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Negative. The current price of 953 is below the 20-day moving average (MA) of 2669.10, below the 50-day MA of 2685.68, and below the 200-day MA of 1680.17, indicating a neutral trend. The MACD of -53.56 indicates Positive momentum. The RSI at 47.18 is Neutral, neither overbought nor oversold. The STOCH value of 47.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4588.
Oncolys BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥137.76B | -14.35 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥74.05B | -44.84 | ― | ― | 0.80% | 32.87% | |
45 Neutral | ¥7.97B | -10.42 | -63.25% | ― | 7.80% | 12.92% | |
45 Neutral | ¥11.04B | -9.38 | ― | ― | ― | 24.17% | |
41 Neutral | ¥120.10B | -34.06 | -10.16% | ― | -59.19% | -124.16% | |
40 Underperform | ¥5.38B | -5.04 | ― | ― | -23.82% | 14.80% |
* Healthcare Sector Average
JP:4588
Oncolys BioPharma, Inc.
2,544.00
1,913.00
303.17%
JP:4587
Peptidream
941.30
-746.70
-44.24%
JP:4564
OncoTherapy Science
19.00
-4.00
-17.39%
JP:4575
CanBas Co., Ltd.
571.00
-388.00
-40.46%
JP:4583
Chiome Bioscience Inc.
68.00
-82.00
-54.67%
JP:4974
Takara Bio Inc.
1,144.00
365.00
46.85%
Oncolys BioPharma, Inc. Corporate Events
Oncolys Wins Full Japanese Approval for First Oncolytic Virus in Esophageal Cancer
Jun 8, 2026
Oncolys BioPharma has secured full marketing approval in Japan for Telomelysin, an oncolytic adenovirus injection for esophageal cancer patients who are not candidates for curative surgery or chemoradiotherapy, marking the first approval of its ki...
Oncolys BioPharma Narrows Quarterly Loss but Withholds 2026 Forecast
May 8, 2026
Oncolys BioPharma reported non-consolidated results for the first quarter ended March 31, 2026, posting net sales of ¥3 million and a narrowed operating loss of ¥420 million, compared with a ¥785 million operating loss a year earlie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.